Characteristics and outcomes of patients hospitalized with COVID-19 at a tertiary hospital in Nigeria

Afr Health Sci. 2023 Mar;23(1):72-82. doi: 10.4314/ahs.v23i1.9.

Abstract

Background: Data regarding the features and outcomes of hospitalized COVID-19 patients in Africa are increasingly available.

Objectives: To describe socio-demographic, clinical and laboratory characteristics and outcomes of COVID-19 patients.

Methods: A cross-sectional study of 86 adult patients hospitalized with COVID-19 between March and November 2020. Characteristics were described in survivors and non-survivors.

Results: Mean age was 60.9±16.1 years, 53(61.6%) were male. Co-morbidities were found in 77(89.5%) patients. On severity, 6(7%) were mild, 23(26.7%) moderate, 51(59.3%) severe and 6(7%) critical. Oxygen saturation and respiratory rate were 71±22% and 38±11/minute in non-survivors and 90±7% and 31±7/minute in survivors respectively (p<0.001, p<0.001)). Overall mortality was 47.7% with no death among patients with mild disease and deaths in all patients with critical disease. Duration of hospitalization was 2.0(1.0-4.5) days in those who died and 12(7.0-15.0) days in those who survived (p<0.001). Of the 42 patients that received dexamethasone, 11(26.2%) died, while 31(73.8%) survived (p=<0.001).

Conclusion: Most of the patients had co-morbidities and there was high mortality in patients with severe and critical COVID-19. Mean oxygen saturation was low and respiratory rate high overall. Factors associated with mortality included: Significantly greater hypoxia and tachypnea, less dexamethasone use and shorter hospitalization.

Keywords: COVID-19; COVID-19 mortality; SARS CoV-2.

MeSH terms

  • Adult
  • Aged
  • COVID-19* / epidemiology
  • COVID-19* / therapy
  • Cross-Sectional Studies
  • Dexamethasone
  • Female
  • Hospitalization
  • Humans
  • Male
  • Middle Aged
  • Nigeria / epidemiology
  • Retrospective Studies
  • SARS-CoV-2
  • Tertiary Care Centers

Substances

  • Dexamethasone